Encompass Health Co. (NYSE:EHC) Receives $83.22 Average PT from Analysts

Encompass Health Co. (NYSE:EHC) has received a consensus rating of “Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $90.29.

EHC has been the subject of a number of recent analyst reports. Barclays upped their price target on shares of Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Stephens reiterated an “overweight” rating and issued a $85.00 price target on shares of Encompass Health in a research note on Tuesday, January 16th. Mizuho upped their price objective on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Truist Financial lifted their target price on Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Friday, February 9th. Finally, Raymond James restated a “strong-buy” rating and issued a $95.00 price target (up from $85.00) on shares of Encompass Health in a research note on Friday, April 26th.

Encompass Health Trading Down 0.6 %

NYSE:EHC opened at $82.84 on Thursday. The firm has a market capitalization of $8.30 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 1.31 and a beta of 0.94. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.28. The business has a fifty day moving average price of $78.64 and a 200-day moving average price of $71.25. Encompass Health has a one year low of $57.55 and a one year high of $85.84.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.93 by $0.19. The firm had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.88 earnings per share. Sell-side analysts forecast that Encompass Health will post 4.1 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Monday, April 1st were given a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.72%. The ex-dividend date was Thursday, March 28th. Encompass Health’s dividend payout ratio is presently 16.22%.

Insider Buying and Selling at Encompass Health

In other news, CEO Mark J. Tarr sold 44,976 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total value of $3,745,151.52. Following the sale, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Encompass Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EHC. International Assets Investment Management LLC purchased a new stake in Encompass Health during the 4th quarter valued at $20,210,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Encompass Health by 2.3% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company’s stock worth $87,989,000 after acquiring an additional 29,926 shares during the last quarter. Phocas Financial Corp. boosted its stake in shares of Encompass Health by 112.4% during the 4th quarter. Phocas Financial Corp. now owns 99,875 shares of the company’s stock worth $6,664,000 after purchasing an additional 52,847 shares during the period. Nordea Investment Management AB grew its holdings in Encompass Health by 21.0% during the 4th quarter. Nordea Investment Management AB now owns 101,705 shares of the company’s stock valued at $6,787,000 after purchasing an additional 17,684 shares during the last quarter. Finally, Oak Thistle LLC raised its position in Encompass Health by 19.1% in the 4th quarter. Oak Thistle LLC now owns 14,436 shares of the company’s stock worth $963,000 after purchasing an additional 2,319 shares during the period. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.